The authors thank an individual who contributed significantly to this paper and wishes to remain anonymous and declined authorship or acknowledgement.
Supported by International Myopia Institute. The publication costs of the International Myopia Institute reports were supported by donations from the Brien Holden Vision Institute, Carl Zeiss Vision, Coopervision, Essilor, Alcon, and Vision Impact Institute.
Disclosure: L. Jones, Alcon (F, C, R), Allergan (F), Contamac (F), CooperVision (F, C, R), Essilor (F), GL Chemtec (F), Inflamax Research (F), Johnson & Johnson Vision (F, C, R), Menicon (F), Nature's Way (F), Novartis (F, C, R), Ophtecs (C, R), Safilens (F), Santen (F), Shire (F), SightGlass (F), TearLab (F), TearScience (F), Visioneering (F); B. Drobe, Essilor (E), P; J.M. González-Méijome, Alcon (F, C, R), Bausch & Lomb (C, R), CooperVision (F, C, R), Essilor (F), Johnson & Johnson Vision (F), Menicon (F), Paragon Vision Science (F), Procornea (F, C, R); L. Gray, None; T. Kratzer, Carl Zeiss Vision GmbH (E), P; S. Newman, Menicon Co. Pty Ltd. (E), P; J.J. Nichols, Alcon, (C, R), Bruder Healthcare (F, C), Allergan (F, C), Kala Pharmaceuticals (F, C), Olympic Ophthalmics (C), Shire (C), Johnson & Johnson Vision Care (F), Sun Pharmaceuticals (C), ScienceBased Health (C), Oyster Point (C), Sight Sciences (C), Silk Technologies (C), Topivert (C), TearSolutions (F), Tearfilm Innovations (I); A. Ohlendorf, Carl Zeiss Vision International GmbH, (F, E); S. Ramdass, Bausch & Lomb (F, C), Contamac (F), Euclid (F), Paragon Vision Sciences (F, R), Specialeyes (F), SynergEyes (F), Wink Production Inc. (R); J. Santodomingo-Rubido, Menicon Company Ltd. (E); K.L. Schmid, Carl Zeiss Vision (F); D. Tan, Santen (F, C, R), Eye-Lens (C), P; K.-O. Tan, Brian Holden Vision Institute (E); F.A. Vera-Diaz, None; Y.-L. Wong, Essilor International R and D (E); K.L. Gifford, Alcon (R), Coopervision (C, R), Menicon (C, R), Visioneering Technologies (R), Myopia Profile Pty Ltd. (I); S. Resnikoff, Brien Holden Vision Institute (C)